<DOC>
	<DOC>NCT01938612</DOC>
	<brief_summary>This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor followed by an expansion phase in patients with advanced solid tumors.</brief_summary>
	<brief_title>A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>In the doseescalation phase: patients with advanced solid tumors refractory to standard treatment, intolerant of standard treatment, or for which no standard therapy exists. In the doseexpansion phase: histologically or cytologicallyconfirmed advanced or metastatic biliary tract cancer (BTC), esophagus cancer(EC) (squamous cell carcinoma) or squamous cell carcinoma of the head and neck (SCCHN). men or women. Eastern Cooperative Oncology Group (ECOG) status of 0 or 1. Adequate organ and marrow function. Subjects must have at least 1 measurable lesion. Available archived tumor tissue sample. Willingness to provide consent for biopsy samples. Any prior Grade â‰¥ 3 irAE while receiving immunotherapy Prior exposure to any antiPD1 or antiPDL1 antibody Active or prior documented autoimmune disease within the past 2 years History of primary immunodeficiency Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment Women who are pregnant or lactating Uncontrolled intercurrent illness Known history of tuberculosis Known to be human immunodeficiency virus (HIV) positive Hepatitis B or C infection Other invasive malignancy within 5 years</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MEDI4736</keyword>
	<keyword>Advanced solid tumors</keyword>
	<keyword>squamous cell carcinoma of the head and Neck</keyword>
	<keyword>biliary tract cancer</keyword>
	<keyword>squamous cell carcinoma of esophagus cancer</keyword>
	<keyword>B7-H1</keyword>
	<keyword>PD-L1</keyword>
</DOC>